FDA grants Breakthrough Therapy Designation status for acalabrutinib
European Pharmaceutical Review | August 01, 2017
AstraZeneca and Acerta Pharma – its haematology R&D centre of excellence – have announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib. This potential drug aims to treat patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor in development for the treatment of multiple B-cell cancers.